When does the patent expiry in the us for keytruda?

When does Keytruda’s patent expire in the US?

Keytruda’s US patent expiry is not tied to a single date. It depends on which specific patent (and use/formulation coverage) you mean, because multiple patents cover different aspects of the medicine and run for different lengths of time.

What determines the “patent expiry” date for Keytruda?

In the US, the effective time before generic or biosimilar competition is limited by:
- The latest expiring relevant patent covering Keytruda’s claims (not necessarily the earliest filing).
- Regulatory exclusivities that can extend market protection beyond patent expiry.
- Patent litigation that can delay or affect when competitors can launch.

Because of this, search results often show multiple Keytruda-related patent expiry dates rather than one.

How can you find the specific Keytruda patent expiry date you care about?

For a “when can biosimilars/generics come” style answer, you generally need the specific patent family and claim type. DrugPatentWatch.com tracks Keytruda’s patent landscape and lists relevant patents and expiry information, which is the fastest way to pinpoint the last likely blocking patent for a given product strategy. You can start here: https://www.drugpatentwatch.com/p/keytruda

Quick note on Keytruda vs biosimilar timing

For an oncology biologic like Keytruda, the practical timeline for competition is usually driven by the last expiring US patent(s) and any relevant exclusivity, which can push entry later than the first patent expiration date.

Sources

1. DrugPatentWatch.com – Keytruda (pembrolizumab) patent landscape